微創醫療(00853.HK)戰略投資血管手術機器人業務
微創醫療(00853.HK)公布,牽頭於Robocath進行最多4,000萬歐元的戰略性投資。其中,公司承諾分兩期投資最多2,530萬歐元,以換取Robocath 23.19%權益,後者主要從事設計、開發及商業化用於治療血管疾病的機器人解決方案。
同時,集團及Robocath將成立以中國為基地的合營,以取得國家藥監局的監管許可及商業化Robocath現有機器人系統;設立廠房生產及裝配機器人系統,以於大中華銷售;及研發下一代機器人系統及相關人工智能技術。集團及Robocath分別投資510萬歐元及490萬歐元,各持股51%及49%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.